Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,200,000 shares, a decline of 8.4% from the October 15th total of 1,310,000 shares. Based on an average daily volume of 588,400 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wells Fargo & Company dropped their price target on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 16th. Citigroup cut their target price on Charles River Laboratories International to $280.00 in a research note on Tuesday, August 9th. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a research report on Thursday, September 29th. Deutsche Bank Aktiengesellschaft lowered their price objective on Charles River Laboratories International from $290.00 to $270.00 in a research report on Monday, August 8th. Finally, StockNews.com assumed coverage on shares of Charles River Laboratories International in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $298.42.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $250.07 on Wednesday. The stock has a market capitalization of $12.72 billion, a P/E ratio of 29.45, a PEG ratio of 1.62 and a beta of 1.28. The business has a 50 day simple moving average of $208.35 and a two-hundred day simple moving average of $219.21. Charles River Laboratories International has a 12 month low of $181.36 and a 12 month high of $397.77. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.40 and a quick ratio of 1.14.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 534 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $216.36, for a total value of $115,536.24. Following the sale, the executive vice president now owns 20,232 shares in the company, valued at approximately $4,377,395.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Neuberger Berman Group LLC lifted its position in Charles River Laboratories International by 3.0% during the third quarter. Neuberger Berman Group LLC now owns 257,514 shares of the medical research company’s stock worth $50,599,000 after buying an additional 7,565 shares in the last quarter. State Street Corp grew its position in shares of Charles River Laboratories International by 0.9% in the 3rd quarter. State Street Corp now owns 2,031,141 shares of the medical research company’s stock valued at $399,729,000 after buying an additional 19,084 shares during the last quarter. Northeast Financial Consultants Inc boosted its stake in Charles River Laboratories International by 15.6% in the third quarter. Northeast Financial Consultants Inc now owns 2,073 shares of the medical research company’s stock valued at $408,000 after acquiring an additional 279 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Charles River Laboratories International by 1.4% during the third quarter. Public Employees Retirement System of Ohio now owns 26,145 shares of the medical research company’s stock worth $5,145,000 after purchasing an additional 353 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Charles River Laboratories International by 36.6% during the third quarter. Thrivent Financial for Lutherans now owns 83,567 shares of the medical research company’s stock worth $16,446,000 after purchasing an additional 22,411 shares in the last quarter. 95.20% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.